Treatment of ST Elevation Myocardial Infarction from Fibrinolysis to Primary PCI: In Terms of Risks and Benefits.

Simple item page
dc.contributor.authorKhafaji, Hadi A R Hadi
dc.contributor.authorAl-Suwaidi, Jassim M
dc.date.accessioned2017-01-03T09:27:51Z
dc.date.available2017-01-03T09:27:51Z
dc.date.issued2015
dc.description.abstractThe treatment of ST elevation myocardial infarction (STEMI) has undergone significant advances over the past three decades. Current practice guidelines raise the importance of promptly restoring normal coronary blood flow and myocardial perfusion in the infarct zone after the onset of chest pain, through either pharmacologic or mechanical reperfusion strategies. Fibrinolytic therapy remains the most widely used reperfusion strategy worldwide. With the development of newer fibrinolytic agents and adjuvant potent anti-platelets therapies, this approach carries an increased risk of bleeding complications. The current research present up-date review of the use of reperfusion strategies for the treatment of STEMI, using data through the search of MEDLINE, PubMed, EMBASE, as well as related extracts from the annual report of the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. We summarized data from the available studies conducted over the past last 30 years in relation to pharmacologic reperfusion therapy in regards to risks and benefits. Conclusion: Fibrinolytic therapy remains the main reperfusion strategy used for the treatment of STMI worldwide. In the current era, there is a lack of fibrinolytic therapy trials, mainly because of increased focus in mechanical reperfusion therapies’ studies in the developed world. Clinical trials on the use of the fibrinolytics with newer platelet agents are urgently needed.en_US
dc.identifier.citationKhafaji Hadi A R Hadi, Al-Suwaidi Jassim M. Treatment of ST Elevation Myocardial Infarction from Fibrinolysis to Primary PCI: In Terms of Risks and Benefits. Cardiology and Angiology An International Journal. 2015; 3(1): 40-77.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/181010
dc.language.isoenen_US
dc.source.urihttps://www.sciencedomain.org/abstract/6871en_US
dc.subjectFibrinolytic agentsen_US
dc.subjectstreptokinaseen_US
dc.subjectretaplaseen_US
dc.subjectalteplaseen_US
dc.subjecttenecteplaseen_US
dc.subjectacute myocardial infarctionen_US
dc.subjectpatency rateen_US
dc.subjectbleedingen_US
dc.subjectintracranial hemorrhageen_US
dc.titleTreatment of ST Elevation Myocardial Infarction from Fibrinolysis to Primary PCI: In Terms of Risks and Benefits.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
caij2015v3n1p40.pdf
Size:
492.22 KB
Format:
Adobe Portable Document Format
Description:
Systematic review article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Cardiology and Angiology: An International Journal